Olmesartan and atorvastatin are effective in improving circulating progenitor cells profile in hypertensive subjects
Abstract
Data di Pubblicazione:
2012
Abstract:
Background. MicroRNAs (miRs) 221 and 222 have been identified
in circulating progenitor cells (CPCs); miRs are involved in the regulation of cell proliferation, differentiation and angiogenesis.
Previously we found that in CPCs from hypertensive patients
without additional risk for CAD, miR221/222 are increased and associated with cell number and production of reactive oxygen species (ROS). The aim of the present study was to evaluate whether in hypertensives a treatment with olmesartan may have effects on the number of CPCs and on levels of miR221/222 and ROS. We also evaluated whether additional effects may be obtained with an add-on treatment with atorvastatin.
methods. We included 41 hypertensives with no additional risk
factor for CAD and 22 matched controls; we evaluated circulating
CD34+cell number, intracellular miR221/222 and ROS levels at
baseline (T0) and after a six months treatment with 20 mg/die of
olmesartan (T1); blood pressure, fibrinogen, CRP, glucose and lipid profile were also evaluated. Then, hypertensives were randomized to receive an add-on treatment with atorvastatin 20 mg/die (T2a), or to continue with olmesartan alone (T2p) for further 3 months. All parameters were evaluated at the end of the study period.
Results. At T1, systolic and diastolic blood pressure, ROS and
miR221/222 were significantly decreased (all p<0.001) with respect to T0, while the number of cells was increased (p<0.001). CRP and fibrinogen levels were also reduced (p<0.001). After the treatment with atorvastatin (T2a) ROS, miRs, CRP and fibrinogen levels were further decreased (all p <0.005), and CPCs significantly higher (p=0.007); blood pressure values also were further reduced, while lipid profile amelioration didn’t reached the statistical significance. At T2p no further changes were detected as compared to T1.
Conclusions. Olmesartan is effective in reducing miRs and ROS
levels in CPCs from hypertensives, as well as in increasing CPC
number. An add-on treatment with atorvastatin may improve these effects.
in circulating progenitor cells (CPCs); miRs are involved in the regulation of cell proliferation, differentiation and angiogenesis.
Previously we found that in CPCs from hypertensive patients
without additional risk for CAD, miR221/222 are increased and associated with cell number and production of reactive oxygen species (ROS). The aim of the present study was to evaluate whether in hypertensives a treatment with olmesartan may have effects on the number of CPCs and on levels of miR221/222 and ROS. We also evaluated whether additional effects may be obtained with an add-on treatment with atorvastatin.
methods. We included 41 hypertensives with no additional risk
factor for CAD and 22 matched controls; we evaluated circulating
CD34+cell number, intracellular miR221/222 and ROS levels at
baseline (T0) and after a six months treatment with 20 mg/die of
olmesartan (T1); blood pressure, fibrinogen, CRP, glucose and lipid profile were also evaluated. Then, hypertensives were randomized to receive an add-on treatment with atorvastatin 20 mg/die (T2a), or to continue with olmesartan alone (T2p) for further 3 months. All parameters were evaluated at the end of the study period.
Results. At T1, systolic and diastolic blood pressure, ROS and
miR221/222 were significantly decreased (all p<0.001) with respect to T0, while the number of cells was increased (p<0.001). CRP and fibrinogen levels were also reduced (p<0.001). After the treatment with atorvastatin (T2a) ROS, miRs, CRP and fibrinogen levels were further decreased (all p <0.005), and CPCs significantly higher (p=0.007); blood pressure values also were further reduced, while lipid profile amelioration didn’t reached the statistical significance. At T2p no further changes were detected as compared to T1.
Conclusions. Olmesartan is effective in reducing miRs and ROS
levels in CPCs from hypertensives, as well as in increasing CPC
number. An add-on treatment with atorvastatin may improve these effects.
Tipologia CRIS:
14.a.6 Abstract in rivista
Elenco autori:
Mamone, Francesco; Mandraffino, Giuseppe; Mamone, Federica; Mandraffino, Rossella; Napoli, Francesca; Russo, Massimiliano; LO GULLO, Alberto; Creazzo, Michele; Imbalzano, E.; Saitta, Carlo; Castaldo, Maria; Sardo, Maria Adriana; Saitta, Antonino
Link alla scheda completa:
Pubblicato in: